Stanley Druckenmiller
BLTE

Stanley Druckenmiller’s Belite Bio BLTE Stock Holding History

Stanley Druckenmiller’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3M Hold
106,100
– – 0.31% 63
2026
Q1 		$16.9M Buy
+106,100
New +$17.8M 0.5% 43

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Stanley Druckenmiller's BLTE Position: Q2 2026 in Review

Stanley Druckenmiller held its Belite Bio (BLTE) position steady in Q2 2026 at 106,100 shares worth $16.3M. The position accounts for 0.31% of the portfolio, ranked #63.

Stanley Druckenmiller first reported a position in BLTE in Q1 2026 and has held it in 2 quarters since. The position peaked at $16.9M in Q1 2026. 80 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • Stanley Druckenmiller held 106,100 shares of Belite Bio worth $16.3M as of Q2 2026.
  • Stanley Druckenmiller left its Belite Bio share count unchanged in Q2 2026.
  • Belite Bio made up 0.31% of Stanley Druckenmiller's portfolio in Q2 2026, its #63 holding.
  • Stanley Druckenmiller first reported a position in Belite Bio in Q1 2026 and has held it in 2 quarters since.
  • Stanley Druckenmiller's Belite Bio position peaked at $16.9M in Q1 2026.
  • 80 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Duquesne Family Office's 13F filing for Q2 2026, filed 14 Aug 2026.